{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:12:15Z","timestamp":1794017535739,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"DoD","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}]},{"name":"NIAID, NIH"},{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adjuvants play an important role in modulating antigen-specific immune responses. We conducted a comparative adjuvant immunogenicity study in Rhesus macaques using HIV-1 subtype B gp120 envelope protein, B.63521, formulated with aluminum hydroxide gel (AH), or a family of liposomal adjuvants known as Army Liposome Formulation (ALF). ALF comprises saturated phospholipids, cholesterol, and monophosphoryl lipid A. Inclusion of QS-21 or adsorption of the antigen to AH, followed by the addition of ALF, generates ALFQ and ALFA, while inclusion of both immunostimulants generates ALFQA. Priming with canarypox vector ALVAC, followed by boosting with ALVAC and gp120 formulated with each of the four adjuvants, resulted in ALFQ and ALFQA outperforming AH and ALFA vaccine formulations with a high frequency of antigen-specific plasma cells in the bone marrow, robust antibodies, and Env-specific polyfunctional CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses. Transcriptomic analyses revealed upregulation of antiviral and innate immune pathways, thus highlighting ALFQ as a highly potent adjuvant.\n                  <\/jats:p>","DOI":"10.1038\/s41541-025-01322-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T11:15:59Z","timestamp":1766142959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates"],"prefix":"10.1038","volume":"11","author":[{"given":"Shikha","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina K.","family":"Peachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Alving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Nettere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Arif","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung V.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorean","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Swafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar","family":"Machmach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Misicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Mutascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousman","family":"Jobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zemil McCrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke S.","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Polonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Paquin-Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pollara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl R.","family":"Alving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmi","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genoveffa","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton F.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Ake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"1322_CR1","unstructured":"UNAIDS. UNAIDS Data 2024 (UNAIDS, 2024)."},{"key":"1322_CR2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JVI.02544-12","volume":"87","author":"P Pegu","year":"2013","unstructured":"Pegu, P. et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87, 1708\u20131719 (2013).","journal-title":"J. Virol."},{"key":"1322_CR3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","volume":"349","author":"DH Barouch","year":"2015","unstructured":"Barouch, D. H. et al. HIV-1 vaccines. Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320\u2013324 (2015).","journal-title":"Science"},{"key":"1322_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40430-7","volume":"14","author":"VS Bollimpelli","year":"2023","unstructured":"Bollimpelli, V. S. et al. Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques. Nat. Commun. 14, 4789 (2023).","journal-title":"Nat. Commun."},{"key":"1322_CR5","volume":"15","author":"MA Rahman","year":"2024","unstructured":"Rahman, M. A. et al. Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response. Nat. Commun. 15, 9102 (2024).","journal-title":"Nat. Commun."},{"key":"1322_CR6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","volume":"384","author":"GE Gray","year":"2021","unstructured":"Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089\u20131100 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1473-3099(24)00358-X","volume":"24","author":"GE Gray","year":"2024","unstructured":"Gray, G. E. et al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo\/HVTN 705\/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 24, 1201\u20131212 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1322_CR9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209\u20132220 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR10","volume":"24","author":"J Kim","year":"2021","unstructured":"Kim, J., Vasan, S., Kim, J. H. & Ake, J. A. Current approaches to HIV vaccine development: a narrative review. J. Int. AIDS Soc. 24, e25793 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"1322_CR11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","volume":"12","author":"ML Robb","year":"2012","unstructured":"Robb, M. L. et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 12, 531\u2013537 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"1322_CR12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","volume":"366","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275\u20131286 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR13","first-page":"228ra238","volume":"6","author":"AW Chung","year":"2014","unstructured":"Chung, A. W. et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228ra238 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33, 610\u2013616 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR15","volume":"384","author":"Z Xie","year":"2024","unstructured":"Xie, Z. et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 384, eadk0582 (2024).","journal-title":"Science"},{"key":"1322_CR16","volume":"6","author":"KO Saunders","year":"2021","unstructured":"Saunders, K. O. et al. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines 6, 50 (2021).","journal-title":"NPJ Vaccines"},{"key":"1322_CR17","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adk9550","volume":"9","author":"TG Caniels","year":"2024","unstructured":"Caniels, T. G. et al. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Sci. Immunol. 9, eadk9550 (2024).","journal-title":"Sci. Immunol."},{"key":"1322_CR18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47492-1","volume":"15","author":"A Koornneef","year":"2024","unstructured":"Koornneef, A. et al. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits. Nat. Commun. 15, 3128 (2024).","journal-title":"Nat. Commun."},{"key":"1322_CR19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0000000000003438","volume":"96","author":"N Garrett","year":"2024","unstructured":"Garrett, N. et al. Safety and immunogenicity of a DNA vaccine with subtype C gp120 protein adjuvanted with MF59 or AS01B: a phase 1\/2a HIV-1 vaccine trial. J. Acquir. Immune Defic. Syndr. 96, 350\u2013360 (2024).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1322_CR20","doi-asserted-by":"publisher","unstructured":"Hahn, W. O. et al. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20240604 (2024).","DOI":"10.1084\/jem.20240604"},{"key":"1322_CR21","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgae529","volume":"3","author":"P Yousefpour","year":"2024","unstructured":"Yousefpour, P. et al. Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin\/monophosphoryl lipid A nanoparticle. PNAS Nexus 3, pgae529 (2024).","journal-title":"PNAS Nexus"},{"key":"1322_CR22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","volume":"19","author":"CR Alving","year":"2020","unstructured":"Alving, C. R., Peachman, K. K., Matyas, G. R., Rao, M. & Beck, Z. Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev. Vaccines 19, 279\u2013292 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"1322_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent, A. M. et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev. Vaccines 16, 55\u201363 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"1322_CR24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","volume":"227","author":"I Leroux-Roels","year":"2023","unstructured":"Leroux-Roels, I. et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial. J. Infect. Dis. 227, 761\u2013772 (2023).","journal-title":"J. Infect. Dis."},{"key":"1322_CR25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens, M. B. RTS,S\/AS01 vaccine (Mosquirix): an overview. Hum. Vaccin Immunother. 16, 480\u2013489 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"1322_CR26","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"1322_CR27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1102524","volume":"14","author":"CR Alving","year":"2023","unstructured":"Alving, C. R., Rao, M. & Matyas, G. R. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21. Front. Immunol. 14, 1102524 (2023).","journal-title":"Front. Immunol."},{"key":"1322_CR28","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0264-410X(02)00174-3","volume":"20","author":"CR Alving","year":"2002","unstructured":"Alving, C. R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20, S56\u2013S64 (2002).","journal-title":"Vaccine"},{"key":"1322_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00638-6","volume":"8","author":"S Shrivastava","year":"2023","unstructured":"Shrivastava, S. et al. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. NPJ Vaccines 8, 43 (2023).","journal-title":"NPJ Vaccines"},{"key":"1322_CR30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2018.02.006","volume":"275","author":"Z Beck","year":"2018","unstructured":"Beck, Z., Torres, O. B., Matyas, G. R., Lanar, D. E. & Alving, C. R. Immune response to antigen adsorbed to aluminum hydroxide particles: effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J. Control. Release 275, 12\u201319 (2018).","journal-title":"J. Control. Release"},{"key":"1322_CR31","doi-asserted-by":"publisher","unstructured":"Verma, A. et al. Impact of T(h)1 CD4 follicular helper T cell skewing on antibody responses to an HIV-1 vaccine in rhesus macaques. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01737-19 (2020).","DOI":"10.1128\/JVI.01737-19"},{"key":"1322_CR32","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1016\/j.vaccine.2022.08.048","volume":"40","author":"JN Hutter","year":"2022","unstructured":"Hutter, J. N. et al. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults. Vaccine 40, 5781\u20135790 (2022).","journal-title":"Vaccine"},{"key":"1322_CR33","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","volume":"5","author":"BL Ober Shepherd","year":"2024","unstructured":"Ober Shepherd, B. L. et al. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with army liposome formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. Lancet Microbe. 5, e581\u2013e593 (2024).","journal-title":"Lancet Microbe"},{"key":"1322_CR34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add5960","volume":"16","author":"M Prabhakaran","year":"2024","unstructured":"Prabhakaran, M. et al. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates. Sci. Transl. Med. 16, eadd5960 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR35","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1322_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195\u2013204 (2014).","journal-title":"Nat. Immunol."},{"key":"1322_CR37","doi-asserted-by":"publisher","unstructured":"Kasturi, S. P. et al. 3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abb1025 (2020).","DOI":"10.1126\/sciimmunol.abb1025"},{"key":"1322_CR38","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1093\/infdis\/jiad434","volume":"230","author":"ZM Chirenje","year":"2024","unstructured":"Chirenje, Z. M. et al. Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. J. Infect. Dis. 230, e405\u2013e415 (2024).","journal-title":"J. Infect. Dis."},{"key":"1322_CR39","volume":"10","author":"BS Ou","year":"2024","unstructured":"Ou, B. S. et al. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Sci. Adv. 10, eadn7187 (2024).","journal-title":"Sci. Adv."},{"key":"1322_CR40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1322_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"1322_CR42","doi-asserted-by":"crossref","first-page":"e1002890","DOI":"10.1371\/journal.ppat.1002890","volume":"8","author":"MD Alpert","year":"2012","unstructured":"Alpert, M. D. et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 8, e1002890 (2012).","journal-title":"PLoS Pathog."},{"key":"1322_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15711","volume":"8","author":"T Bradley","year":"2017","unstructured":"Bradley, T. et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat. Commun. 8, 15711 (2017).","journal-title":"Nat. Commun."},{"key":"1322_CR44","doi-asserted-by":"publisher","unstructured":"Ehrenberg, P. K. et al. A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw4236 (2019).","DOI":"10.1126\/scitranslmed.aaw4236"},{"key":"1322_CR45","doi-asserted-by":"publisher","unstructured":"Shangguan, S. et al. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. eLife https:\/\/doi.org\/10.7554\/eLife.69577 (2021).","DOI":"10.7554\/eLife.69577"},{"key":"1322_CR46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41591-018-0161-0","volume":"24","author":"ME Ackerman","year":"2018","unstructured":"Ackerman, M. E. et al. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nat. Med. 24, 1590\u20131598 (2018).","journal-title":"Nat. Med."},{"key":"1322_CR47","doi-asserted-by":"publisher","unstructured":"Chamcha, V. et al. Strong T(H)1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav1800 (2019).","DOI":"10.1126\/scitranslmed.aav1800"},{"key":"1322_CR48","doi-asserted-by":"crossref","first-page":"19940","DOI":"10.1073\/pnas.0907898106","volume":"106","author":"A Benlahrech","year":"2009","unstructured":"Benlahrech, A. et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. USA 106, 19940\u201319945 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1322_CR49","first-page":"663","volume":"7","author":"I Welsby","year":"2016","unstructured":"Welsby, I. et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21. Front. Immunol. 7, 663 (2016).","journal-title":"Front. Immunol."},{"key":"1322_CR50","doi-asserted-by":"publisher","unstructured":"Rydyznski Moderbacher, C. et al. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI160898 (2022).","DOI":"10.1172\/JCI160898"},{"key":"1322_CR51","doi-asserted-by":"publisher","unstructured":"Rapaka, R. R., Cross, A. S. & McArthur, M. A. Using adjuvants to drive T cell responses for next-generation infectious disease vaccines. Vaccines https:\/\/doi.org\/10.3390\/vaccines9080820 (2021).","DOI":"10.3390\/vaccines9080820"},{"key":"1322_CR52","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","volume":"86","author":"M Bonsignori","year":"2012","unstructured":"Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521\u201311532 (2012).","journal-title":"J. Virol."},{"key":"1322_CR53","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.00718-12","volume":"87","author":"SM Alam","year":"2013","unstructured":"Alam, S. M. et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 87, 1554\u20131568 (2013).","journal-title":"J. Virol."},{"key":"1322_CR54","doi-asserted-by":"publisher","unstructured":"Shen, X. et al. HIV-1 gp120 and modified vaccinia virus Ankara (MVA) gp140 boost immunogens increase immunogenicity of a DNA\/MVA HIV-1 vaccine. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01077-17 (2017).","DOI":"10.1128\/JVI.01077-17"},{"key":"1322_CR55","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.00412-15","volume":"89","author":"L Wieczorek","year":"2015","unstructured":"Wieczorek, L. et al. Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. J. Virol. 89, 7478\u20137493 (2015).","journal-title":"J. Virol."},{"key":"1322_CR56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","volume":"485","author":"DC Montefiori","year":"2009","unstructured":"Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395\u2013405 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1322_CR57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1322_CR58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2011.09.007","volume":"375","author":"CA Todd","year":"2012","unstructured":"Todd, C. A. et al. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J. Immunol. Methods 375, 57\u201367 (2012).","journal-title":"J. Immunol. Methods"},{"key":"1322_CR59","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.chom.2022.06.005","volume":"30","author":"SS Li","year":"2022","unstructured":"Li, S. S. et al. HLA-B *46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. Cell Host Microbe 30, 1173\u20131185 e1178 (2022).","journal-title":"Cell Host Microbe"},{"key":"1322_CR60","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"1322_CR61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907\u2013915 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1322_CR63","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"1322_CR64","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-4-2","volume":"4","author":"GD Bader","year":"2003","unstructured":"Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4, 2 (2003).","journal-title":"BMC Bioinformatics"},{"key":"1322_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00407-3","volume":"6","author":"PV Scaria","year":"2021","unstructured":"Scaria, P. V. et al. Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. NPJ Vaccines 6, 148 (2021).","journal-title":"NPJ Vaccines"},{"key":"1322_CR66","doi-asserted-by":"crossref","first-page":"e0194266","DOI":"10.1371\/journal.pone.0194266","volume":"13","author":"Y Wen","year":"2018","unstructured":"Wen, Y. et al. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLoS ONE 13, e0194266 (2018).","journal-title":"PLoS ONE"},{"key":"1322_CR67","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/infdis\/jiy348","volume":"218","author":"M Rao","year":"2018","unstructured":"Rao, M. et al. Liposome-encapsulated human immunodeficiency virus-1 gp120 induces potent V1V2-specific antibodies in humans. J. Infect. Dis. 218, 1541\u20131550 (2018).","journal-title":"J. Infect. Dis."},{"key":"1322_CR68","doi-asserted-by":"crossref","first-page":"e1008764","DOI":"10.1371\/journal.ppat.1008764","volume":"16","author":"K Om","year":"2020","unstructured":"Om, K. et al. Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathog. 16, e1008764 (2020).","journal-title":"PLoS Pathog."},{"key":"1322_CR69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4161\/mabs.25077","volume":"5","author":"B Clemenceau","year":"2013","unstructured":"Clemenceau, B. et al. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. mAbs 5, 587\u2013594 (2013).","journal-title":"mAbs"},{"key":"1322_CR70","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.4049\/jimmunol.1900572","volume":"203","author":"MA Rahman","year":"2019","unstructured":"Rahman, M. A. et al. Differential effect of mucosal NKp44(+) innate lymphoid cells and deltagamma cells on simian immunodeficiency virus infection outcome in rhesus macaques. J. Immunol. 203, 2459\u20132471 (2019).","journal-title":"J. Immunol."},{"key":"1322_CR71","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cyto.a.21084","volume":"79","author":"J Pollara","year":"2011","unstructured":"Pollara, J. et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79, 603\u2013612 (2011).","journal-title":"Cytometry A"},{"key":"1322_CR72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cyto.a.23348","volume":"93","author":"J Pollara","year":"2018","unstructured":"Pollara, J. et al. Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. Cytometry A 93, 436\u2013447 (2018).","journal-title":"Cytometry A"},{"key":"1322_CR73","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","volume":"88","author":"J Pollara","year":"2014","unstructured":"Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88, 7715\u20137726 (2014).","journal-title":"J. Virol."},{"key":"1322_CR74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"1322_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).","journal-title":"J. Immunol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01322-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:05:14Z","timestamp":1767474314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01322-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R.A. and Z.B. are co-inventors on US and International patents for ALFQ. C.R.A. and G.R.M. are co-inventors on a US patent for the use of ALFQ in a malaria vaccine. Both patents are owned by the US Army. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}